WAG
VRTX icon

Winthrop Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Winthrop Advisory Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$295K Buy
594
+105
+21% +$46.5K 0.02% 175
2026
Q1 		$218K Buy
+489
New +$228K 0.02% 178

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Winthrop Advisory Group's VRTX Position: Q2 2026 in Review

Winthrop Advisory Group increased its Vertex Pharmaceuticals (VRTX) stake by 21% in Q2 2026, buying an estimated $46.5K and bringing the position to 594 shares worth $295K. The position accounts for 0.02% of the portfolio, ranked #175.

Winthrop Advisory Group first reported a position in VRTX in Q1 2026 and has held it in 2 quarters since. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Winthrop Advisory Group held 594 shares of Vertex Pharmaceuticals worth $295K as of Q2 2026.
  • Winthrop Advisory Group bought 105 Vertex Pharmaceuticals shares in Q2 2026, an estimated $46.5K.
  • Vertex Pharmaceuticals made up 0.02% of Winthrop Advisory Group's portfolio in Q2 2026, its #175 holding.
  • Winthrop Advisory Group first reported a position in Vertex Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Winthrop Advisory Group's 13F filing for Q2 2026, filed 17 Jul 2026.